Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection~* Chronic HCV infection~* Subject must be HCV treatment-naïve or have failed prior HCV treatment~* Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease~Exclusion Criteria:~* Positive test result at screening for Hepatitis B surface antigen or anti-human immunodeficiency virus (anti-HIV) antibody~* HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype~* Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-493/ABT-530

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).